HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 3, 2007, Pages 275-278

  Phillips, Andrew N ^a   Gilson, Richard ^b   Easterbrook, Philippa ^b   Fisher, Martin ^b   Gazzard, Brian ^b   Johnson, Margaret ^b   Walsh, John ^b   Leen, Clifford ^b   Orkin, Chloe ^b   Anderson, Jane ^b   Pillay, Deenan ^b   Delpech, Valerie ^b   Schwenk, Achim ^b   Dunn, David ^b   Gompels, Mark ^b   Hill, Teresa ^b   Porter, Kholoud ^b   Babiker, Abdel ^b   Sabin, Caroline ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

Antiretroviral therapy; CD4 count decline; Presentation; When to start

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COUNT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 37349075406     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181514441     Document Type: Article

References (16)

1. Lampe FC, Smith CJ, Madge S, et al. Success of HIV clinical care according to demographic group among sexually-infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med. 2007;167:692-700.
2. Lampe FC, Gatell J, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy. A multi-cohort analysis, 1996 to 2002. Arch Intern Med. 2006;166:521-528.
3. Phillips AN, Dunn D, Sabin C, et al; UK HIV Drug Resistance Database. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487-494.
4. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor in patients with triple class resistant virus [abstract 105aLB]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
5. The SMART Study Group; El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
6. Smit C, Geskus R, Walker S, et al; The CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749.
7. Weber R, Sabin CA, Friis-Muller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.
8. d'Arminio Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS-defining malignancies: results from the D:A:D study [abstract 84]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
9. Baker J, Peng G, Rapkin J, et al. HIV-related immune suppression after ART predicts risk of non-opportunistic diseases: results from the FIRST study [abstract 37]. Presented at: Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
10. Phillips AN, Gazzard B, Clumeck N, et al. When should antiretroviral therapy for HIV be started? BMJ. 2007;334:76-78.
11. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) study. HIV Med. 2004;5:115-124.
12. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
13. Lepri AC, Sabin CA, Pezzotti P, et al. Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion study. J Infect Dis. 1997;175:775-780.
14. Cascade Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr. 2003;34:76-83.
15. The UK CHIC Steering Committee. Rate of AIDS diseases or death in HIV infected antiretroviral therapy-naive individuals with high CD4 count. AIDS. (in press).
16. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.